Konu "Rituximab" için Tıp Fakültesi listeleme
Toplam kayıt 7, listelenen: 1-7
-
Are chondrocytes damaged when rheumatologic inflammation is suppressed?
(Taylor & Francis Inc, 2017)Aim: The use of biological agents (BAs) for treating diseases such as rheumatoid arthritis (RA), spondyloarthropathy, and systemic lupus erythematosus to reduce inflammation has been fruitful. Especially as part of the ... -
Atypical multiple cutaneous ulcers in a patient with systemic lupus erythematosus treated with rituximab: Case report
(Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.S., 2016)Intravenous rituximab therapy is an effective treatment alternative for systemic lupus erythematosus patients for whom standard therapies have not been effective. We report on a 20- year-old male with intractable systemic ... -
Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: Results from the TURKBİO registry
(Turkiye Klinikleri, 2023)Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine ... -
Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
(Elsevier Ltd, 2023)Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) ... -
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
(Springer, 2023)Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ... -
Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
(CIG Media Group, 2020)Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
(2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ...